Tagged with Hong Kong

Hong Kong Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology milestones, comments on the affiliate’s push to enhance clinical trials in alignment with mainland China, local talent development and the…

Hong Kong OASES was established to position Hong Kong as a global innovation and technology hub, with significant investments in infrastructure and funding, particularly focusing on life and health sciences, AI, fintech, and advanced manufacturing. VP for Life and Health Technology Dr Maggie Lo outlines how OASES actively engages with strategic companies worldwide…

Hong Kong One year since our last conversation, the Hong Kong Institute of Biotechnology’s Gina Jiang introduces the significant strides made in setting up a GMP facility for CAR-T cell therapy manufacturing at HKIB. Regulatory frameworks have now been developed to support clinical trials and the rollout of advanced therapies. Jiang highlights…

Hong Kong A surgeon by training, Prof Philip Chiu is now dean of the Faculty of Medicine at the research-focused Chinese University of Hong Kong (CUHK). He shares the creation of CUHK’s Multiscale Medical Robotics Centre and the robotic system for minimally invasive surgery developed there; CUHK’s focus on translational medicine and…

Hong Kong The City University of Hong Kong (CityUHK) has a well-earned reputation as an innovative hub for research and professional education. Michael Yang, Senior VP of Innovation and Enterprise, professor of biomedical sciences, and director of the Tung Biomedical Sciences Centre at CityUHK, explains some of its pioneering iniciatives, such as…

Hong Kong Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the population is aged 65 or older. In addition, she outlines Eisai’s oncology and neurology-focused portfolio; the potential provided by Hong…

Hong Kong Dr Juliana Chan, one of Asia’s leading endocrinologists, is also the founding director of GemVCare, a company that provides data to medical professionals to advise patients on diabetes prevention, diagnosis, and treatment based on genetic profiling. In conversation, she discusses some of the key differences in how diabetes manifests in Asian…

Hong Kong Immuno Cure has a unique approach to the failure-ridden field of HIV vaccine development: focusing on a therapeutic vaccine for already infected individuals rather than a preventive vaccine. Founders Tom Lau and Dr Xia Jin explain the company’s origins as a spin-off from the University of Hong Kong’s AIDS Institute…

Hong Kong Arbele is a clinical stage biotech centred on an innovative T-Cell Engager approach to gastrointestinal cancers. Chairman and founder John Luk explains the prevalence of these cancers in China, the company’s challenging clinical trials journey, and the pursuit of breakthrough and fast-track designations in the US and an IND in…

Hong Kong Sabrina Chan, senior executive director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI), an organization that represents the innovative pharmaceutical industry in Hong Kong and Macau, weighs in on regulatory improvements in the territory such as the OnePlus mechanism and the Centre for Medical Products Regulation; discusses HKAPI’s…

Hong Kong Roche has a strong presence in Hong Kong with a local footprint dating back to 1971. Diana Liu, general manager of the Swiss pharma’s Hong Kong & Macau affiliate, outlines its growing local clinical research commitment, one that has seen its clinical trial activities increase 2.5 times and reach an…

Hong Kong Managing director of Otsuka Pharmaceutical Hong Kong Koji Ueda explains the Japanese company’s long-standing presence in Hong Kong, which dates back to 1956, the affiliate’s 50-50 split between pharmaceuticals and nutraceuticals and within pharma its principal focus on nephrology and CNS. Moreover, he explains the milestone launch of Otsuka’s first-in-class…